Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Should A Biosimilar Sponsor Do The 'Patent Dance?' It Depends On Many Things

Executive Summary

The amount of exclusivity remaining for a reference product, strength of an innovator's patents and risk of a preliminary injunction are factors that biosimilar sponsors should consider in deciding whether to follow the BPCIA's patent information and exchange procedures, one legal expert suggests.

Advertisement

Related Content

US FDA's Biosimilars Chief Leah Christl Plans Departure
Biosimilar Global Reference Standard Intrigues US FDA, But Many Questions Still To Answer
Biosimilar Global Reference Standard Intrigues US FDA, But Many Questions Still To Answer
Implementing User Fees Should Be Lighter Lift For FDA This Time Around; Bill Heads To White House
US Supreme Court Permits Earlier Biosimilar Launches; Penalty For Declining Patent Dance Uncertain
Biosimilar Tentative Approvals Could Flow From US Supreme Court Case
Biosimilar User Fee Agreement Offers FDA Funding Boost, Fee Structure Overhaul

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS121297

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel